Mild Traumatic Brain Injury (mTBI) is a major consequence of head concussion. mTBI can result in long-term complications or death.
people per year in Europe are affect [1], mostly children, elderly, sportsmen and military forces who have the higher incidence.
In the US, mTBI generates 2,5 million of emergency unit visits
and 300,000 hospitalizations per year.
Only a small proportion of mTBI patients (6-8%) have a confirmation by CT-scan of a brain injury requiring hospital stay. More than 90% of patients are discharged after the CT-scan [2].
Current practice is to perform a CT-scan that is costly, exposes patients to irradiation, and can only be carried out in equipped hospitals and clinics leading to long waiting times for patients in over-stressed emergency departments. Costs for CT-Scan are evaluated at 250 million € per year in Europe and in addition to 2 billion € of indirect costs.
The solution
With a drop of blood from a finger prick at the point of care, TBICheck™ allows to rapidly discharge patients with a suspected brain injury.
TBICheck™ can avoid the CT-scan for approximately half of the traumatic brain injury patients by improving patients’ triage, thus reducing the burden for patients and decreasing healthcare costs.
ABCDx has identified a combination of biomarkers to detect the brain lesion using a drop of blood from a finger prick and permits to discharge with 100% certainty half of the mTBI patients with no brain injury within
With a drop of blood from a finger prick at the point of care, TBICheck™ allows to rapidly discharge patients with a suspected brain injury.
TBICheck™ is a breakthrough innovation providing the first immediate diagnostic test at the point of care that enables mTBI detection for currently underdiagnosed patients, especially in sport and military fields, retirement homes and in pediatric population.
